$SBPH Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in F-star Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in F-star Therapeutics, Inc.. Get notifications about new insider transactions in F-star Therapeutics, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 07 2021 | SBPH | F-star Therapeutic ... | Benz Edward JR | Director | Option Exercise | A | 6.88 | 20,000 | 137,600 | 20,000 | |
| Jun 07 2021 | SBPH | F-star Therapeutic ... | Arkowitz David | Director | Option Exercise | A | 6.88 | 20,000 | 137,600 | 20,000 | |
| Mar 11 2021 | SBPH | F-star Therapeutic ... | Forster Eliot | President and CEO | Option Exercise | A | 7.24 | 127,924 | 926,170 | 388,901 | |
| Mar 11 2021 | SBPH | F-star Therapeutic ... | Brewis Neil | Chief Scientific Of ... | Option Exercise | A | 7.24 | 22,561 | 163,342 | 99,180 | |
| Mar 11 2021 | SBPH | F-star Therapeutic ... | DEPTULA-HICKS DARLENE M | Treasurer and CFO | Option Exercise | A | 7.24 | 25,894 | 187,473 | 54,320 | |
| Mar 11 2021 | SBPH | F-star Therapeutic ... | Kayitalire Louis | Chief Medical Offic ... | Option Exercise | A | 7.24 | 12,880 | 93,251 | 40,169 | |
| Feb 02 2021 | SBPH | F-star Therapeutic ... | Forster Eliot | President and CEO | Grant | A | 0.00 | 142,000 | 0 | 160,560 | 18.6 K to 160.6 K (+765.09 %) |
| Feb 02 2021 | SBPH | F-star Therapeutic ... | Kayitalire Louis | Chief Medical Offic ... | Grant | A | 0.00 | 29,000 | 0 | 55,437 | 26.4 K to 55.4 K (+109.69 %) |
| Feb 02 2021 | SBPH | F-star Therapeutic ... | Bermingham Nessan | Director | Grant | A | 0.00 | 87,000 | 0 | 103,875 | 16.9 K to 103.9 K (+515.56 %) |
| Feb 02 2021 | SBPH | F-star Therapeutic ... | Benz Edward JR | Director | Grant | A | 0.00 | 4,385 | 0 | 4,385 | 0 to 4.4 K |
| Feb 02 2021 | SBPH | F-star Therapeutic ... | DEPTULA-HICKS DARLENE M | Treasurer and CFO | Grant | A | 0.00 | 30,000 | 0 | 56,437 | 26.4 K to 56.4 K (+113.48 %) |
| Oct 01 2020 | SBPH | Spring Bank Pharma ... | Brady Todd C | Director | Grant | A | 0.00 | 9,235 | 0 | 60,016 | 50.8 K to 60 K (+18.19 %) |
| Oct 01 2020 | SBPH | Spring Bank Pharma ... | CLACKSON TIMOTHY P | Director | Grant | A | 0.00 | 9,422 | 0 | 50,486 | 41.1 K to 50.5 K (+22.94 %) |
| Jul 01 2020 | SBPH | Spring Bank Pharma ... | Brady Todd C | Director | Grant | A | 0.00 | 8,418 | 0 | 50,781 | 42.4 K to 50.8 K (+19.87 %) |
| Jul 01 2020 | SBPH | Spring Bank Pharma ... | CLACKSON TIMOTHY P | Director | Grant | A | 0.00 | 8,588 | 0 | 41,064 | 32.5 K to 41.1 K (+26.44 %) |
| Jun 25 2020 | SBPH | Spring Bank Pharma ... | CLACKSON TIMOTHY P | Director | Option Exercise | A | 1.60 | 7,500 | 12,000 | 7,500 | |
| Jun 25 2020 | SBPH | Spring Bank Pharma ... | Klein Pamela M. | Director | Option Exercise | A | 1.60 | 7,500 | 12,000 | 7,500 | |
| Jun 25 2020 | SBPH | Spring Bank Pharma ... | Brady Todd C | Director | Option Exercise | A | 1.60 | 7,500 | 12,000 | 7,500 | |
| Jun 25 2020 | SBPH | Spring Bank Pharma ... | Smith Scott Andrew | Director | Option Exercise | A | 1.60 | 7,500 | 12,000 | 7,500 | |
| Jun 25 2020 | SBPH | Spring Bank Pharma ... | Eichler Kurt M | Director | Option Exercise | A | 1.60 | 7,500 | 12,000 | 7,500 | |
| Jun 25 2020 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Option Exercise | A | 1.60 | 7,500 | 12,000 | 7,500 | |
| Apr 01 2020 | SBPH | Spring Bank Pharma ... | Brady Todd C | Director | Grant | A | 0.00 | 13,306 | 0 | 42,363 | 29.1 K to 42.4 K (+45.79 %) |
| Apr 01 2020 | SBPH | Spring Bank Pharma ... | CLACKSON TIMOTHY P | Director | Grant | A | 0.00 | 13,575 | 0 | 32,476 | 18.9 K to 32.5 K (+71.82 %) |
| Mar 09 2020 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Option Exercise | A | 0.00 | 40,000 | 0 | 40,000 | |
| Mar 09 2020 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Option Exercise | A | 1.41 | 40,000 | 56,400 | 40,000 | |
| Mar 09 2020 | SBPH | Spring Bank Pharma ... | Iyer Radhakrishnan P. | Chief Scientific Of ... | Option Exercise | A | 0.00 | 20,000 | 0 | 20,000 | |
| Mar 09 2020 | SBPH | Spring Bank Pharma ... | Iyer Radhakrishnan P. | Chief Scientific Of ... | Option Exercise | A | 1.41 | 20,000 | 28,200 | 20,000 | |
| Mar 09 2020 | SBPH | Spring Bank Pharma ... | Freve Jonathan | CFO & Treasurer | Option Exercise | A | 0.00 | 25,000 | 0 | 25,000 | |
| Mar 09 2020 | SBPH | Spring Bank Pharma ... | Freve Jonathan | CFO & Treasurer | Option Exercise | A | 1.41 | 25,000 | 35,250 | 25,000 | |
| Jan 02 2020 | SBPH | Spring Bank Pharma ... | Smith Scott Andrew | Director | Grant | A | 0.00 | 12,500 | 0 | 37,476 | 25 K to 37.5 K (+50.05 %) |
| Jan 02 2020 | SBPH | Spring Bank Pharma ... | Eichler Kurt M | Director | Sell | S | 1.26 | 40,000 | 50,540 | 549,273 | 589.3 K to 549.3 K (-6.79 %) |
| Jan 02 2020 | SBPH | Spring Bank Pharma ... | CLACKSON TIMOTHY P | Director | Grant | A | 0.00 | 7,991 | 0 | 18,901 | 10.9 K to 18.9 K (+73.24 %) |
| Jan 02 2020 | SBPH | Spring Bank Pharma ... | Brady Todd C | Director | Grant | A | 0.00 | 7,832 | 0 | 29,057 | 21.2 K to 29.1 K (+36.90 %) |
| Jan 02 2020 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Grant | A | 0.00 | 9,098 | 0 | 37,929 | 28.8 K to 37.9 K (+31.56 %) |
| Nov 14 2019 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Buy | P | 2.83 | 5,000 | 14,150 | 90,400 | 85.4 K to 90.4 K (+5.85 %) |
| Oct 01 2019 | SBPH | Spring Bank Pharma ... | Smith Scott Andrew | Director | Grant | A | 0.00 | 5,741 | 0 | 24,976 | 19.2 K to 25 K (+29.85 %) |
| Oct 01 2019 | SBPH | Spring Bank Pharma ... | CLACKSON TIMOTHY P | Director | Grant | A | 0.00 | 3,670 | 0 | 10,910 | 7.2 K to 10.9 K (+50.69 %) |
| Oct 01 2019 | SBPH | Spring Bank Pharma ... | Smith Scott Andrew | Director | Grant | A | 0.00 | 5,741 | 0 | 24,976 | 19.2 K to 25 K (+29.85 %) |
| Oct 01 2019 | SBPH | Spring Bank Pharma ... | CLACKSON TIMOTHY P | Director | Grant | A | 0.00 | 3,670 | 0 | 10,910 | 7.2 K to 10.9 K (+50.69 %) |
| Oct 01 2019 | SBPH | Spring Bank Pharma ... | Brady Todd C | Director | Grant | A | 0.00 | 3,597 | 0 | 21,225 | 17.6 K to 21.2 K (+20.41 %) |
| Oct 01 2019 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Grant | A | 0.00 | 4,179 | 0 | 28,831 | 24.7 K to 28.8 K (+16.95 %) |
| Oct 01 2019 | SBPH | Spring Bank Pharma ... | Brady Todd C | Director | Grant | A | 0.00 | 3,597 | 0 | 21,225 | 17.6 K to 21.2 K (+20.41 %) |
| Oct 01 2019 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Grant | A | 0.00 | 4,179 | 0 | 28,831 | 24.7 K to 28.8 K (+16.95 %) |
| Jul 11 2019 | SBPH | Spring Bank Pharma ... | Smith Scott Andrew | Director | Option Exercise | A | 4.62 | 7,500 | 34,650 | 7,500 | |
| Jul 11 2019 | SBPH | Spring Bank Pharma ... | Klein Pamela M. | Director | Option Exercise | A | 4.62 | 15,000 | 69,300 | 15,000 | |
| Jul 11 2019 | SBPH | Spring Bank Pharma ... | Eichler Kurt M | Director | Option Exercise | A | 4.62 | 7,500 | 34,650 | 7,500 | |
| Jul 11 2019 | SBPH | Spring Bank Pharma ... | CLACKSON TIMOTHY P | Director | Option Exercise | A | 4.62 | 7,500 | 34,650 | 7,500 | |
| Jul 11 2019 | SBPH | Spring Bank Pharma ... | Brady Todd C | Director | Option Exercise | A | 4.62 | 7,500 | 34,650 | 7,500 | |
| Jul 11 2019 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Option Exercise | A | 4.62 | 7,500 | 34,650 | 7,500 | |
| Jul 11 2019 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Option Exercise | A | 4.62 | 7,500 | 34,650 | 7,500 | |
| Jul 01 2019 | SBPH | Spring Bank Pharma ... | Smith Scott Andrew | Director | Grant | A | 0.00 | 5,352 | 0 | 19,235 | 13.9 K to 19.2 K (+38.55 %) |
| Jul 01 2019 | SBPH | Spring Bank Pharma ... | CLACKSON TIMOTHY P | Director | Grant | A | 0.00 | 3,421 | 0 | 7,240 | 3.8 K to 7.2 K (+89.58 %) |
| Jul 01 2019 | SBPH | Spring Bank Pharma ... | Brady Todd C | Director | Grant | A | 0.00 | 3,354 | 0 | 17,628 | 14.3 K to 17.6 K (+23.50 %) |
| Jul 01 2019 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Grant | A | 0.00 | 3,896 | 0 | 24,652 | 20.8 K to 24.7 K (+18.77 %) |
| Jun 28 2019 | SBPH | Spring Bank Pharma ... | Smith Scott Andrew | Director | Buy | P | 4.09 | 12,000 | 49,080 | 13,883 | 1.9 K to 13.9 K (+637.28 %) |
| May 29 2019 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Buy | P | 6.03 | 10,000 | 60,300 | 85,400 | 75.4 K to 85.4 K (+13.26 %) |
| May 29 2019 | SBPH | Spring Bank Pharma ... | Freve Jonathan | CFO & Treasurer | Buy | P | 5.40 | 5,000 | 27,000 | 12,482 | 7.5 K to 12.5 K (+66.83 %) |
| May 22 2019 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Buy | P | 6.63 | 5,000 | 33,150 | 75,400 | 70.4 K to 75.4 K (+7.10 %) |
| Apr 30 2019 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Buy | P | 7.36 | 5,000 | 36,800 | 70,400 | 65.4 K to 70.4 K (+7.65 %) |
| Apr 30 2019 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Buy | P | 7.31 | 5,000 | 36,550 | 65,400 | 60.4 K to 65.4 K (+8.28 %) |
| Apr 02 2019 | SBPH | Spring Bank Pharma ... | Smith Scott Andrew | Director | Grant | A | 0.00 | 1,883 | 0 | 1,883 | 0 to 1.9 K |
| Apr 02 2019 | SBPH | Spring Bank Pharma ... | CLACKSON TIMOTHY P | Director | Grant | A | 0.00 | 1,204 | 0 | 3,819 | 2.6 K to 3.8 K (+46.04 %) |
| Jan 25 2019 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Option Exercise | A | 10.35 | 50,000 | 517,500 | 50,000 | |
| Jan 25 2019 | SBPH | Spring Bank Pharma ... | Freve Jonathan | CFO & Treasurer | Option Exercise | A | 10.35 | 50,000 | 517,500 | 50,000 | |
| Jan 25 2019 | SBPH | Spring Bank Pharma ... | Iyer Radhakrishnan P. | Chief Scientific Of ... | Option Exercise | A | 10.35 | 45,000 | 465,750 | 45,000 | |
| Jan 25 2019 | SBPH | Spring Bank Pharma ... | Afdhal Nezam H. | Chief Medical Offic ... | Option Exercise | A | 10.35 | 50,000 | 517,500 | 50,000 | |
| Oct 03 2018 | SBPH | Spring Bank Pharma ... | BARDON CHRISTIANA | Director | Grant | A | 0.00 | 831 | 0 | 2,296 | 1.5 K to 2.3 K (+56.72 %) |
| Oct 02 2018 | SBPH | Spring Bank Pharma ... | CLACKSON TIMOTHY P | Director | Grant | A | 0.00 | 788 | 0 | 1,532 | 744 to 1.5 K (+105.91 %) |
| Aug 17 2018 | SBPH | Spring Bank Pharma ... | Smith Scott Andrew | Director | Option Exercise | A | 11.34 | 11,000 | 124,740 | 11,000 | |
| Aug 17 2018 | SBPH | Spring Bank Pharma ... | Smith Scott Andrew | Director | Option Exercise | A | 11.34 | 11,000 | 124,740 | 11,000 | |
| Aug 13 2018 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Buy | P | 12.02 | 4,000 | 48,080 | 60,400 | 56.4 K to 60.4 K (+7.09 %) |
| Jul 03 2018 | SBPH | Spring Bank Pharma ... | Eichler Kurt M | Director | Grant | A | 0.00 | 957 | 0 | 587,097 | 586.1 K to 587.1 K (+0.16 %) |
| Jul 03 2018 | SBPH | Spring Bank Pharma ... | CLACKSON TIMOTHY P | Director | Grant | A | 0.00 | 744 | 0 | 744 | 0 to 744 |
| Jul 03 2018 | SBPH | Spring Bank Pharma ... | BARDON CHRISTIANA | Director | Grant | A | 0.00 | 824 | 0 | 1,465 | 641 to 1.5 K (+128.55 %) |
| Jun 19 2018 | SBPH | Spring Bank Pharma ... | BARDON CHRISTIANA | Director | Option Exercise | A | 13.99 | 5,500 | 76,945 | 5,500 | |
| Jun 19 2018 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Option Exercise | A | 13.99 | 5,500 | 76,945 | 5,500 | |
| Jun 19 2018 | SBPH | Spring Bank Pharma ... | Bates Jonathan | Director | Option Exercise | A | 13.99 | 5,500 | 76,945 | 5,500 | |
| Jun 19 2018 | SBPH | Spring Bank Pharma ... | Brady Todd C | Director | Option Exercise | A | 13.99 | 5,500 | 76,945 | 5,500 | |
| Jun 19 2018 | SBPH | Spring Bank Pharma ... | Eichler Kurt M | Director | Option Exercise | A | 13.99 | 5,500 | 76,945 | 5,500 | |
| Apr 03 2018 | SBPH | Spring Bank Pharma ... | BARDON CHRISTIANA | Director | Grant | A | 0.00 | 641 | 0 | 641 | 0 to 641 |
| Apr 03 2018 | SBPH | Spring Bank Pharma ... | Eichler Kurt M | Director | Grant | A | 0.00 | 773 | 0 | 586,140 | 585.4 K to 586.1 K (+0.13 %) |
| Mar 05 2018 | SBPH | Spring Bank Pharma ... | CLACKSON TIMOTHY P | Director | Option Exercise | A | 13.10 | 11,000 | 144,100 | 11,000 | |
| Mar 01 2018 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Buy | P | 12.83 | 1,000 | 12,830 | 56,400 | 55.4 K to 56.4 K (+1.81 %) |
| Jan 17 2018 | SBPH | Spring Bank Pharma ... | Iyer Radhakrishnan P. | Chief Scientific Of ... | Option Exercise | A | 12.10 | 40,000 | 484,000 | 40,000 | |
| Jan 17 2018 | SBPH | Spring Bank Pharma ... | Freve Jonathan | CFO & Treasurer | Option Exercise | A | 12.10 | 27,000 | 326,700 | 27,000 | |
| Jan 17 2018 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Option Exercise | A | 12.10 | 80,000 | 968,000 | 80,000 | |
| Jan 17 2018 | SBPH | Spring Bank Pharma ... | Afdhal Nezam H. | Chief Medical Offic ... | Option Exercise | A | 12.10 | 50,000 | 605,000 | 50,000 | |
| Oct 30 2017 | SBPH | Spring Bank Pharma ... | BARDON CHRISTIANA | Director | Option Exercise | A | 15.17 | 11,000 | 166,870 | 11,000 | |
| Oct 03 2017 | SBPH | Spring Bank Pharma ... | Eichler Kurt M | Director | Grant | A | 0.00 | 919 | 0 | 584,388 | 583.5 K to 584.4 K (+0.16 %) |
| Sep 14 2017 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Buy | P | 14.84 | 1,000 | 14,840 | 55,400 | 54.4 K to 55.4 K (+1.84 %) |
| Aug 07 2017 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Buy | P | 12.24 | 2,300 | 28,152 | 19,386 | 17.1 K to 19.4 K (+13.46 %) |
| Aug 07 2017 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Buy | P | 12.25 | 200 | 2,450 | 17,086 | 16.9 K to 17.1 K (+1.18 %) |
| Aug 03 2017 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Buy | P | 12.43 | 1,000 | 12,430 | 54,400 | 53.4 K to 54.4 K (+1.87 %) |
| Aug 03 2017 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Buy | P | 12.28 | 1,000 | 12,280 | 53,400 | 52.4 K to 53.4 K (+1.91 %) |
| Jul 05 2017 | SBPH | Spring Bank Pharma ... | Eichler Kurt M | Director | Grant | A | 0.00 | 936 | 0 | 583,469 | 582.5 K to 583.5 K (+0.16 %) |
| Jun 27 2017 | SBPH | Spring Bank Pharma ... | Eichler Kurt M | Director | Buy | P | 13.00 | 76,923 | 999,999 | 582,533 | 505.6 K to 582.5 K (+15.21 %) |
| Jun 16 2017 | SBPH | Spring Bank Pharma ... | Eichler Kurt M | Director | Option Exercise | A | 14.27 | 5,500 | 78,485 | 5,500 | |
| Jun 16 2017 | SBPH | Spring Bank Pharma ... | Brady Todd C | Director | Option Exercise | A | 14.27 | 5,500 | 78,485 | 5,500 | |
| Jun 16 2017 | SBPH | Spring Bank Pharma ... | Bates Jonathan | Director | Option Exercise | A | 14.27 | 5,500 | 78,485 | 5,500 | |
| Jun 16 2017 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Option Exercise | A | 14.27 | 5,500 | 78,485 | 5,500 | |
| Mar 07 2017 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Buy | P | 9.44 | 2,000 | 18,880 | 52,400 | 50.4 K to 52.4 K (+3.97 %) |
| Feb 27 2017 | SBPH | Spring Bank Pharma ... | Eichler Kurt M | Director | Buy | P | 8.76 | 1,200 | 10,516 | 1,200 | 0 to 1.2 K |
| Feb 10 2017 | SBPH | Spring Bank Pharma ... | Freve Jonathan | CFO & Treasurer | Option Exercise | A | 7.66 | 20,000 | 153,200 | 20,000 | |
| Feb 10 2017 | SBPH | Spring Bank Pharma ... | Afdhal Nezam H. | Chief Medical Offic ... | Option Exercise | A | 7.66 | 40,000 | 306,400 | 40,000 | |
| Feb 10 2017 | SBPH | Spring Bank Pharma ... | Iyer Radhakrishnan P. | Chief Scientific Of ... | Option Exercise | A | 7.66 | 40,000 | 306,400 | 40,000 | |
| Feb 10 2017 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Option Exercise | A | 7.66 | 80,000 | 612,800 | 80,000 | |
| Jan 06 2017 | SBPH | Spring Bank Pharma ... | Eichler Kurt M | Director | Grant | A | 0.00 | 3,520 | 0 | 505,610 | 502.1 K to 505.6 K (+0.70 %) |
| Dec 16 2016 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Buy | P | 8.50 | 2,000 | 17,000 | 50,400 | 48.4 K to 50.4 K (+4.13 %) |
| Dec 01 2016 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Buy | P | 7.98 | 2,000 | 15,960 | 48,400 | 46.4 K to 48.4 K (+4.31 %) |
| Nov 23 2016 | SBPH | Spring Bank Pharma ... | Freve Jonathan | CFO, Treasurer & Se ... | Option Exercise | A | 10.79 | 5,482 | 59,151 | 5,482 | |
| Nov 23 2016 | SBPH | Spring Bank Pharma ... | Freve Jonathan | CFO, Treasurer & Se ... | Grant | A | 9.12 | 5,482 | 49,996 | 7,482 | 2 K to 7.5 K (+274.10 %) |
| Nov 23 2016 | SBPH | Spring Bank Pharma ... | Afdhal Nezam H. | Chief Medical Offic ... | Option Exercise | A | 10.79 | 13,150 | 141,889 | 13,150 | |
| Nov 23 2016 | SBPH | Spring Bank Pharma ... | Afdhal Nezam H. | Chief Medical Offic ... | Grant | A | 9.12 | 13,150 | 119,928 | 53,300 | 40.2 K to 53.3 K (+32.75 %) |
| Nov 23 2016 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Option Exercise | A | 10.79 | 21,900 | 236,301 | 21,900 | |
| Nov 23 2016 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Grant | A | 9.12 | 21,900 | 199,728 | 46,400 | 24.5 K to 46.4 K (+89.39 %) |
| Nov 23 2016 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Option Exercise | A | 10.79 | 4,386 | 47,325 | 4,386 | |
| Nov 23 2016 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Grant | A | 9.12 | 4,386 | 40,000 | 16,886 | 12.5 K to 16.9 K (+35.09 %) |
| Nov 23 2016 | SBPH | Spring Bank Pharma ... | Brady Todd C | Director | Option Exercise | A | 10.79 | 10,964 | 118,302 | 10,964 | |
| Nov 23 2016 | SBPH | Spring Bank Pharma ... | Brady Todd C | Director | Grant | A | 9.12 | 10,964 | 99,992 | 10,964 | 0 to 11 K |
| Nov 23 2016 | SBPH | Spring Bank Pharma ... | Eichler Kurt M | Director | Option Exercise | A | 10.79 | 64,100 | 691,639 | 64,100 | |
| Nov 23 2016 | SBPH | Spring Bank Pharma ... | Eichler Kurt M | Director | Grant | A | 9.12 | 64,100 | 584,592 | 502,090 | 438 K to 502.1 K (+14.64 %) |
| Nov 10 2016 | SBPH | Spring Bank Pharma ... | Eichler Kurt M | Director | Buy | P | 8.69 | 7,000 | 60,830 | 437,990 | 431 K to 438 K (+1.62 %) |
| Nov 10 2016 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Buy | P | 8.84 | 2,000 | 17,680 | 24,500 | 22.5 K to 24.5 K (+8.89 %) |
| Sep 20 2016 | SBPH | Spring Bank Pharma ... | Eichler Kurt M | Director | Buy | P | 12.50 | 1,346 | 16,825 | 430,990 | 429.6 K to 431 K (+0.31 %) |
| Sep 20 2016 | SBPH | Spring Bank Pharma ... | Eichler Kurt M | Director | Buy | P | 12.50 | 650 | 8,125 | 429,644 | 429 K to 429.6 K (+0.15 %) |
| Sep 15 2016 | SBPH | Spring Bank Pharma ... | Eichler Kurt M | Director | Buy | P | 12.50 | 514 | 6,425 | 428,994 | 428.5 K to 429 K (+0.12 %) |
| Sep 14 2016 | SBPH | Spring Bank Pharma ... | Eichler Kurt M | Director | Buy | P | 12.50 | 490 | 6,125 | 428,480 | 428 K to 428.5 K (+0.11 %) |
| Sep 12 2016 | SBPH | Spring Bank Pharma ... | Afdhal Nezam H. | Chief Medical Offic ... | Buy | P | 12.50 | 2,400 | 30,000 | 40,150 | 37.8 K to 40.2 K (+6.36 %) |
| Sep 02 2016 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Buy | P | 11.75 | 1,000 | 11,750 | 22,500 | 21.5 K to 22.5 K (+4.65 %) |
| Aug 31 2016 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Buy | P | 12.41 | 1,000 | 12,410 | 21,500 | 20.5 K to 21.5 K (+4.88 %) |
| Aug 24 2016 | SBPH | Spring Bank Pharma ... | Afdhal Nezam H. | Chief Medical Offic ... | Buy | P | 12.00 | 350 | 4,200 | 37,750 | 37.4 K to 37.8 K (+0.94 %) |
| Aug 24 2016 | SBPH | Spring Bank Pharma ... | Afdhal Nezam H. | Chief Medical Offic ... | Buy | P | 11.99 | 100 | 1,199 | 37,400 | 37.3 K to 37.4 K (+0.27 %) |
| Aug 24 2016 | SBPH | Spring Bank Pharma ... | Afdhal Nezam H. | Chief Medical Offic ... | Buy | P | 11.90 | 1,550 | 18,445 | 37,300 | 35.8 K to 37.3 K (+4.34 %) |
| Aug 24 2016 | SBPH | Spring Bank Pharma ... | Eichler Kurt M | Director | Buy | P | 10.73 | 3,000 | 32,190 | 427,990 | 425 K to 428 K (+0.71 %) |
| Aug 23 2016 | SBPH | Spring Bank Pharma ... | Freve Jonathan | CFO, Treasurer & Se ... | Buy | P | 10.74 | 1,000 | 10,740 | 2,000 | 1,000 to 2 K (+100.00 %) |
| Aug 22 2016 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Buy | P | 11.66 | 1,000 | 11,660 | 20,500 | 19.5 K to 20.5 K (+5.13 %) |
| Aug 22 2016 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Buy | P | 11.20 | 1,000 | 11,200 | 19,500 | 18.5 K to 19.5 K (+5.41 %) |
| Aug 16 2016 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Buy | P | 11.37 | 1,000 | 11,370 | 18,500 | 17.5 K to 18.5 K (+5.71 %) |
| Aug 16 2016 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Buy | P | 11.20 | 1,000 | 11,200 | 17,500 | 16.5 K to 17.5 K (+6.06 %) |
| Aug 16 2016 | SBPH | Spring Bank Pharma ... | Afdhal Nezam H. | Chief Medical Offic ... | Buy | P | 11.49 | 100 | 1,149 | 35,750 | 35.7 K to 35.8 K (+0.28 %) |
| Aug 16 2016 | SBPH | Spring Bank Pharma ... | Afdhal Nezam H. | Chief Medical Offic ... | Buy | P | 11.43 | 1,800 | 20,574 | 35,650 | 33.9 K to 35.7 K (+5.32 %) |
| Aug 15 2016 | SBPH | Spring Bank Pharma ... | Afdhal Nezam H. | Chief Medical Offic ... | Buy | P | 11.33 | 2,600 | 29,450 | 33,850 | 31.3 K to 33.9 K (+8.32 %) |
| Aug 09 2016 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Buy | P | 11.11 | 1,000 | 11,110 | 16,500 | 15.5 K to 16.5 K (+6.45 %) |
| Aug 09 2016 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Buy | P | 10.94 | 1,000 | 10,940 | 15,500 | 14.5 K to 15.5 K (+6.90 %) |
| Aug 05 2016 | SBPH | Spring Bank Pharma ... | Eichler Kurt M | Director | Buy | P | 9.79 | 1,000 | 9,790 | 424,990 | 424 K to 425 K (+0.24 %) |
| Aug 05 2016 | SBPH | Spring Bank Pharma ... | Freve Jonathan | CFO, Treasurer & Se ... | Buy | P | 9.75 | 1,000 | 9,750 | 1,000 | 0 to 1,000 |
| Aug 05 2016 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Buy | P | 10.15 | 1,000 | 10,150 | 14,500 | 13.5 K to 14.5 K (+7.41 %) |
| Aug 05 2016 | SBPH | Spring Bank Pharma ... | Driscoll Martin J | President and CEO | Buy | P | 9.77 | 1,000 | 9,770 | 13,500 | 12.5 K to 13.5 K (+8.00 %) |
| Jul 29 2016 | SBPH | Spring Bank Pharma ... | Brady Todd C | Director | Option Exercise | A | 9.05 | 11,000 | 99,550 | 11,000 | |
| Jul 29 2016 | SBPH | Spring Bank Pharma ... | Eichler Kurt M | Director | Option Exercise | A | 9.05 | 5,500 | 49,775 | 5,500 |